A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess the Efficacy and Safety of Daily OM-85 Treatment vs. Placebo given in Children Aged 6 Months to 5 Years with Recurrent Wheezing
Phase: 2
Status: Ongoing
Details
This study aims to find out if the proposed study drug, OM-85, a marketed product
in several countries worldwide but not in the US yet, helps make children’s recurrent
wheezing better than other drugs or other types of treatments that are currently available
and approved in the US market.
Sponsor: OM Pharma SA
NCT05857930 - IRB#2023-065